Selvita S.A. (WSE:SLV)

Market Cap	295.16M -56.4%
Revenue (ttm)	349.00M -6.7%
Net Income	-2.08M
EPS	-0.12
Shares Out	18.36M
PE Ratio	n/a
Forward PE	72.84
Dividend	n/a
Ex-Dividend Date	n/a

Volume	34,369
Open	15.96
Previous Close	15.90
Day's Range	15.66 - 16.46
52-Week Range	15.50 - 49.40
Beta	0.21
Analysts	Hold
Price Target	35.85 (+122.95%)
Earnings Date	Nov 19, 2026

About Selvita

Selvita S.A. provides drug discovery, drug development, and contract testing services in Poland. The company offers computer-aided drug design and artificial intelligence solutions, including structure-based drug design, virtual screening, and bioinformatics; medicinal and synthetic, analytical, and solid state chemistry, as well as process chemistry and scale up, and compound management and libraries; structural biology, fragment-based drug discovery, protein production, modification, and characterization; vitro assays and model, mechanistic a...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2007
• Employees: 899
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: SLV

Analyst Summary

According to 6 analysts, the average rating for SLV stock is "Hold." The 12-month stock price target is zł 35.85, which is an increase of 122.95% from the latest price.

Price Target

zł 35.85

(122.95% upside)

Analyst Consensus: Hold

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 4, 2026

Data Sources Report a data error